Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type Abstract
PMID
Authors Arlene O. Siefker-Radtke, Thomas Powles, Victor Moreno, Taek Won Kang, Irfan Cicin, Angela Girvin, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Wei Zhu, Meggan Tammaro, Yohann Loriot
Title Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study
Journal Vol Issue Date Pages Journal Short Title
Journal of Clinical Oncology 41 16_Suppl June 1, 2023
URL https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4504
Abstract Text Background: First-line (1L) therapy for cisplatin (cis)-ineligible pts with mUC remains an unmet need and includes alternative chemotherapy or anti-PD-(L)1 monotherapy for PD-L1 positive tumors. FGFRa tumors are enriched for the luminal 1 subtype with lower immune cell infiltrate and potential lower benefit from anti-PD-(L)1 monotherapy. We studied ERDA+CET in 1L, FGFRa, mUC to determine the potential impact in this setting (NCT03473743). Methods: Pts aged ≥ 18 y with mUC, susceptible FGFRa and measurable disease (no prior systemic therapy for mUC, cis-ineligible) were randomized 1:1 to once-daily ERDA 8 mg (with pharmacodynamically guided uptitration (UpT) to 9 mg) or ERDA 8 mg (no UpT) + IV CET 240 mg every 2 weeks (wks) at cycles 1-4 and 480 mg every 4 wks thereafter. Primary endpoints were investigator-assessed overall response rate (ORR) per RECIST 1.1 and safety; secondary included duration of response (DOR), time to response (TTR), progression free survival (PFS) and overall survival (OS). There were no pre-planned statistical comparisons between treatment arms. Results: As of the data cutoff, 87 pts were randomized and treated; 44 to ERDA+CET and 43 to ERDA: median age was 69 vs 72 y; visceral metastases were present in 60.0 vs 63.6%. Median follow-up time was 14.2 months (mo). ORR for ERDA+CET was 54.5% with 6 (13.6%) CRs and 12 mo OS 68%. 11/24 responders were ongoing. ORR for ERDA was 44.2% with 1 CR and 12 mo OS 56%. 9/19 responders were ongoing. 4 pts in each arm were PD-L1 positive. 3/4 (75%) PD-L1 positive pts responded to ERDA+CET vs 0 for ERDA. The most frequent treatment-emergent AEs (any grade) were hyperphosphatemia (68.9 vs 83.7%), stomatitis (59.1 vs 72.1%) and diarrhea (45.5 vs 48.8%) for ERDA+CET and ERDA respectively. Grade ≥3 treatment-related AEs occurred in 45.5 (ERDA+CET) and 46.5% (ERDA) of pts. There was one CET-related death in ERDA+CET secondary to pulmonary failure. Conclusions: Combination ERDA+CET demonstrated clinically meaningful activity and was well tolerated. These results, in 1L cis-ineligible pts, support previously described activity of ERDA monotherapy in FGFRa mUC. The safety profile was consistent with the known profile for ERDA and CET with no additive toxicity for the combination. Clinical trial information: NCT03473743

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR3 mutant transitional cell carcinoma predicted - sensitive Cetrelimab + Erdafitinib Phase II Actionable In a Phase II trial, the combination of Balversa (erdafitinib) and Cetrelimab (JNJ-63723283) treatment resulted in an overall response rate of 54.5% (6 complete responses), disease control rate of 79.5%, median duration of response of 11.10 months, median progression-free survival of 10.97 months, and a 12-month overall survival of 68% in patients with metastatic urothelial carcinoma harboring FGFR mutations (J Clin Oncol 41, 2023 (suppl 16; abstr 4504); NCT03473743). detail...
FGFR2 mutant transitional cell carcinoma predicted - sensitive Cetrelimab + Erdafitinib Phase II Actionable In a Phase II trial, the combination of Balversa (erdafitinib) and Cetrelimab (JNJ-63723283) treatment resulted in an overall response rate of 54.5% (6 complete responses), disease control rate of 79.5%, median duration of response of 11.10 months, median progression-free survival of 10.97 months, and a 12-month overall survival of 68% in patients with metastatic urothelial carcinoma harboring FGFR mutations (J Clin Oncol 41, 2023 (suppl 16; abstr 4504); NCT03473743). detail...